Page last updated: 2024-09-03

xaliproden and ALS - Amyotrophic Lateral Sclerosis

xaliproden has been researched along with ALS - Amyotrophic Lateral Sclerosis in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abitbol, JL; Corcia, P; Cudkowicz, M; Gordon, PH; Lacomblez, L; Leigh, PN; Meininger, V; Pochigaeva, K	1
Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Meininger, V; Robberecht, W	1
Bensimon, G; Doppler, V; Douillet, P; Lacomblez, L; Meininger, V; Salachas, F	1
Moriwaka, F; Tashiro, K	1

Reviews

3 review(s) available for xaliproden and ALS - Amyotrophic Lateral Sclerosis

Article	Year
Defining survival as an outcome measure in amyotrophic lateral sclerosis. Archives of neurology, 2009, Volume: 66, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Endpoint Determination; Humans; Kaplan-Meier Estimate; Naphthalenes; Outcome Assessment, Health Care; Pentoxifylline; Pyridines; Respiration, Artificial; Respiratory Paralysis; Tracheostomy; Vasodilator Agents	2009
Xaliproden: SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene. Drugs in R&D, 2003, Volume: 4, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Humans; Naphthalenes; Orphan Drug Production; Pyridines; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists	2003
[The advance in the research and therapeutic trials of amyotrophic lateral sclerosis]. Rinsho shinkeigaku = Clinical neurology, 2000, Volume: 40, Issue:12 Topics: Amyotrophic Lateral Sclerosis; Controlled Clinical Trials as Topic; Drug Design; Excitatory Amino Acids; Humans; Naphthalenes; Neuroprotective Agents; Practice Guidelines as Topic; Pyridines; Riluzole	2000

Trials

2 trial(s) available for xaliproden and ALS - Amyotrophic Lateral Sclerosis

Article	Year
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5, Issue:2 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Pyridines	2004
Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5, Issue:2 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Pyridines	2004

Article

Year

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5, Issue:2

Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Pyridines

2004

Xaliproden in amyotrophic lateral sclerosis: early clinical trials.

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5, Issue:2

Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Pyridines

2004